Related Experiment Videos
[Molecular pathology of type 1 primary hyperoxaluria]
P Cochat1, M O Rolland, D Bozon
1Unité de néphrologie pédiatrique, Hôpital Edouard-Herriot et Université Claude Bernard, Lyon.
Nephrologie
|January 1, 1994
Summary
Primary hyperoxaluria type 1, a metabolic disorder, stems from a defective liver enzyme, alanine: glyoxylate aminotransferase (AGT). Genetic defects cause mistargeting of this enzyme, impacting glyoxylate detoxification and leading to oxalosis.
Area of Science:
- Genetics
- Biochemistry
- Metabolic Disorders
Context:
- Primary hyperoxaluria type 1 (PH1) is an inherited metabolic disorder.
- It is characterized by a deficiency in the liver enzyme alanine: glyoxylate aminotransferase (AGT).
- AGT is crucial for detoxifying glyoxylate within peroxisomes.
Purpose:
- To investigate the genetic basis and molecular mechanisms of PH1.
- To understand the relationship between AGT enzyme function, protein expression, and clinical presentation.
- To identify genetic variations and mutations associated with PH1.
Summary:
- PH1 results from defects in the AGT enzyme, leading to glyoxylate accumulation and systemic oxalosis.
- Clinical phenotypes do not correlate with residual AGT activity or immunoreactivity.
- A key feature is the mistargeting of AGT from peroxisomes to mitochondria in certain patient groups.
- The gene for AGT has been localized to chromosome 2q36-37, with identified polymorphisms and point mutations.
Impact:
- Elucidates the molecular pathology of PH1, a common cause of severe kidney disease.
- Provides insights into enzyme targeting and its role in inherited metabolic diseases.
- Facilitates genetic diagnosis and understanding of disease variability in PH1 patients.